1. Орлов Р.С., Ноздрачев А.Д. Нормальная физиология: учебник. М., 2009. 
2. Williams SE, Turnberg LA. Retardation of acid diffusion by pig gastric mucus: a potential role in mucosal protection. Gastroenterology 1980; 79: 299–304. 
3. Devine PL, McKenzie IFC. Mucins: structure, functions and associations with malignancy. Bio Essays 1992; 14 (9); 619–25. 
4. Robert A, Nezamis JE, Lancaster C et al. Mild irritants prevent gastric necrosis through adaptive «cytoprotection» mediated prostaglandins. Am J Physiol 1983; 245: G113–121. 
5. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology 2008; 135: 41–60. 
6. Konturek SJ, Konturek PC, Brzozowski T. Prostaglandins an ulcer healing. J Physiol Pharmacol 2005; 56 (Suppl. 5): 5–31. 
7. Starodub O.T, Demitrack ES, Baumgartner HK, Montrose MH. Disruption of the Cox-1 gene slows repair of microscopic lesions in the mouse gastric epithelium. Am J Physiol Cell Physiol 2008; 294: C223–32. 
8. Uchida M, Tabusa F, Komatsu M et al. Studies on 2(1H)-quinolinone derivatives as gastric antiulcer active agents. 2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl] propionic acid related compounds. Chem Pharm Bull 1985; 33 (9): 3775–86. 
9. Hasegawa S, Sekino H, Matsuoka O et al. Bioequivalence of rebamipide granules and tablets in healthy adult male volunteers. Clin Drug Invest 2003; 23 (12): 771–9. 
10. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 1998; 43 (Suppl. 9): 5S–13S. 
11. Suetsugu H, Ishihara S, Moriyama N et al. Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa. J Lab Clin Med 2000; 136 (1): 50–7. 
12. Ishihara K, Komuro Y, Nishiyama N et al. Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism in rat gastric mucosa. Arzneimittelforschung 1992; 42 (12): 1462–6. 
13. Yoshikawa T, Naito Y, Tanigawa T, Kondo M. Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittelforschung 1993; 43 (3): 363–6. 
14. Sakurai K, Sasabe H, Koga T, Konishi T. Mechanism of hydroxyl radical scavenging by rebamipide: identification of monohydroxylatedrebamipide as a major reaction product. Free Radic Res 2004; 38 (5): 487–94. 
15. Kim JS, Kim JM, Jung HC, Song IS. Expression of cyclooxygenase-2 in human neutrophils activated by Helicobacter pylori water-soluble proteins: possible involvement of NF-kappaB and MAP kinase signaling pathway. Dig Dis Sci 2001; 46 (10): 2277–84. 
16. Yoshida N, Yoshikawa T, Iinuma S et al. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci 1996; 41 (6): 1139–44. 
17. Murakami K, Okajima K, Uchiba M et al. Rebamipide attenuates indomethacin induced gastric mucosal lesion formation by inhibiting activation of leukocytes in rats. Dig Dis Sci 1997; 42 (2): 319–25. 
18. Naito Y, Kuroda M, Mizushima K et al. Transcriptome analysis for cytoprotective actions of rebamipide against indomethacin-induced gastric mucosal injury in rats. 
J Clin Biochem Nutr 2007; 41 (3): 202–10. 
19. Kinjo N, Kawanaka H, Akahoshi T et al. Significance of ERK nitration in portal hypertensive gastropathy and its therapeutic implications. Am J Physiol Gastrointest Liver Physiol 2008; 295 (5): G1016–1024. 
20. Nishizawa T, Suzuki H, Nakagawa I et al. Rebamipide-promoted restoration of gastric mucosal sonic hedgehog expression after early Helicobacter pylori eradication. Digestion 2009; 79 (4): 259–62. 
21. Talley NJ, Riff DS, Schwartz H, Marcuard SP. Double-blind placebo-controlled multicentre studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without Helicobacter pylori infection. Aliment Pharmacol Ther 2001; 15 (10): 1603–11. 
22. Chitapanarux T, Praisontarangkul OA, Lertprasertsuke N. Аn open-labeled study of rebamipide treatment in chronic gastritis pa-tients with dyspeptic symptoms refractory to proton pump inhibitors. Dig Dis Sci 2008; 53 (11): 2896–903. 
23. Tarnawski A, Pai R, Chiou SK et al. Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B. Biochem Biophys Res Commun 2005; 334 (1): 207–12. 
24. Du Y, Li Z, Zhan X et al. Anti-inflammatory effect sofrebamipide according to Helicobacter pylori status in patients with chronicerosi vegastritis: arandomized sucral fate-controlled multicenter trialin China-STARS study. Dig Dis Sci 2008; 53 (11): 2886–95. 
25. Thong-Ngam D, Chayanupatkul M, Klaikeaw N et al. Effect of rebamipide on gastric ulcer healing caused by Helicobacter pylori and/or NSAIDs or non NSAIDs-non H. pylori. J Med Assoc Thai 2009; 92 (9): 1207–12. 
26. Terano A, Arakawa T, Sugiyama T et al. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol 2007; 42 (8): 690–3. 
27. Terano A, Arakawa T, Sugiyama T et al. A pilot study to evaluate a new combination therapy for gastric ulcer: Helicobacter pylori eradication therapy followed by gastroprotective treatment with rebamipide. J Gastroenterol Hepatol 2006; 21 (1 Pt. 1): 103–9. 
28. Shiotani A, Uedo N, Iishi H et al. Re-expression of sonic hedgehog and reduction of CDX2 after Helicobacter pylori eradication prior to incomplete intestinal metaplasia. Int J Cancer 2007; 121 (6): 1182–9. 
29. Shiotani A, Uedo N, Iishi H et al. Predictive factors for metachronous gastric cancer in high-risk patients after successful Helicobacter pylori eradication. Digestion 2008; 78 (2–3): 113–19. 
30. Song KH, Lee YC, Fan DM et al. Healing effects of rebamipide and omeprazole in Helicobacter pylori-positive gastric ulcer patients after eradication therapy: a randomized double-blind, multinational, multi-institutional comparative. Digestion 2011; 84 (3): 221–9. 
31. Kamada T, Sato M, Tokutomi T et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after helicobacter pylori eradication: amulticenter study. Biomed Res Int 2015; 2015: 865–46. 
32. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamipide: over view of its mechanisms of action and efficacy inmucosal protection and ulcer healing. Dig Dis Sci 1998; 43 (Suppl. 9): 5S–13S. 
33. Fujiwara S, Morita Y, Toyonaga T et al. A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection. J Gastroenterol 2011; 46 (5): 595–602. 
34. Kobayashi M, Takeuchi M, Hashimoto S et al. Contributing factors to gastric ulcer healing after endoscopic submucosal dissection including the promoting effect of rebamipide. Dig Dis Sci 2012; 57 (1): 119–26. 
35. Takayama M, Matsui S, Kawasaki М et al. Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers. World J Gastroenterol 2013; 19 (34): 5706–12. 
36. Xiong J, Lai S, Zhang P et al. Rebamipide plus proton pump inhibitor versus proton pump inhibitor alonein the treatment of endoscopic submucosal dissection – induced gastric ulcer: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2014; 93 (12): e64. 
37. Wang J, Guo X, Ye C et al. Efficacy and safety of proton pump inhibitors (PPIs) plus rebamipide for endoscopic submucosal dissection-induced ulcers: a meta-analysis. Intern Med 2014; 53 (12): 1243–8. 
38. Park SH, Cho CS, Lee OY et al. Comparison of prevention of NSAID Induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial – STORM STUDY. J Clin Biochem Nutr 2007; 40 (2): 148–55. 
39. Kim JH, Park SH, Cho CS et al. Preventive Efficacy and Safety of Rebamipide in Nonsteroidal Anti-Inflammatory Drug-Induced Mucosal Toxicity. Gut Liver 2014; 8 (4): 371–9. 
40. Naito Y, Iinuma S, Yagi N et al. Prevention of Indomethacin-induced gastric mucosal injury in Helicobacter pylori-negative healthy volunteers: a comparison study rebamipide vs famotidine. J Clin Biochem Nutr 2008; 43 (1): 34–40. 
41. Kim HK, Kim JI, Kim JK et al. Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. Dig Dis Sci 2007; 52 (8): 1776–82. 
42. Ono S, Kato M, Imai A et al. Preliminary trial of rebamipide for prevention of low-dose aspirin-induced gastric injury in healthy subjects: a randomized, doubleblind, placebo-controlled, cross-over study. J Clin Biochem Nutr 2009; 45 (2): 248–53. 
43. Niwa Y, Nakamura M, Ohmiya N et al. Efficacy of rebamipide for diclofenac induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebocontrolled, cross-over study. J Gastroenterol 2008; 43 (4): 270–6. 
44. Tanigawa T, Watanabe T, Otani K et al. Rebamipide in hibitsindomethacin-induced small intestinalinjury: possibleinvolvementofintestinalmicrobiotamodulationbyupregulation of a-defensin 5. Eur J Pharmacol 2013; 704 (1–3): 64–9. 
45. Suzuki T, Yoshida N, Nakabe N et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci 2008; 106 (3): 469–77. 
46. Hashimoto K, Oshima T, Tomita T et al. Oxidative stress induces gastric epithelial permeability through claudin-3. Biochem Biophys Res Commun 2008; 376 (1): 154–7. 
47. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Exp Rev Gastroenterol Hepatol 2010; 4 (3): 261–70. 
48. Tozawa K, Oshima T, Okugawa T et al. A randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel. Dig Dis Sci 2014; 59 (8): 1885–90. 
49. Sugimoto M, Uotani T, Furuta T. Does rebamipide prevent gastric mucosal injury in patients taking aspirin and clopidogrel? Dig Dis Sci 2014; 59 (8): 1671–3. 
50. Takeuchi K, Takayama S, Hashimoto E et al. Effect of rebamipide on gastric bleeding and ulcerogenic responses induced by aspirin plus clopidogrel under stimulation of acid secretion in rats. J Gastroenterol Hepatol 2014; 29 (Suppl. 4): 37–46. 
51. Watanabe T, Sugimori S, Kameda N et al. Small bowel injury by low-dose entericcoated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 2008; 6 (11): 1279–82. 
52. Toshio W, Toshihisa T, Osamu H et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipid et reatment for low-dose aspirin-induced moderate-to-severe small intestinal damage PLoS ONE 2015; 10 (4): e0122330. 
53. Makiyama K, Takeshima F, Kawasaki H, Zea-Iriarte WL. Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis: a novel therapeutic alternative. Am J Gastroenterol 2000; 95 (7): 1838–9. 
54. Makiyama K, Takeshima F, Hamamoto T. Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis: a prospective study report. Dig Dis Sci 2005; 50 (12): 2323–9. 
55. Miyata M, Kasugai K, Ishikawa T et al. Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis. Dig Dis Sci 2005; 50 (Suppl.1): S119–S123. 
56. Furuta R, Kusugami K, Goto H. Enema therapy for ulcerative colitis patients. Nippon Rinsho 2005; 63 (5): 845–9. 
57. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol 2010; 4 (3): 261–70. 
58. Haruma K, Ito M. Review article: clinical significance of mucosal-protective agents: acid, inflammation, carcinogenesis and rebamipide. Aliment Pharmacol Ther 2003; 18 (1): 153–9.

Е.Ю.Плотникова, Т.Ю.Грачева

ФГБОУ ВО Кемеровский государственный медицинский университет Минздрава России